Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

To Study the Effect of Amorphous Calcium Carbonate (ACC) Treatment on Function and Welfare Improvement in Late-stage Solid Cancer Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03582280
Recruitment Status : Recruiting
First Posted : July 10, 2018
Last Update Posted : April 2, 2019
Sponsor:
Information provided by (Responsible Party):
Amorphical Ltd.

Brief Summary:

An exploratory open label study to improve the function and welfare of late-stage solid cancer subjects (with or without lung involvement) who failed or refused anti-cancer treatment by ACC treatment, administered orally and concomitantly by inhalation.

The following measures will be evaluated: improvement of pain, performance status, dyspnea measurement (Modified Borg Scale)/ oxygen saturation (if applicable) and overall survival.

The subjects' medical charts will be reviewed for their eligibility including the following: medical history, prior cancer treatments, pathologic diagnosis of cancer, and CT/Chest X-ray results. Assessment of prior and concurrent medication use, physician evaluation of patient status, and measurement of Albumin Corrected Serum Calcium level (to be done at baseline and prior to dose escalation, so that results are available prior to the visit) will be performed prior to each dose escalation; in addition, vital signs, ECOG/Karnofsky performance status and VAS pain assessments will be recorded at each visit as well. CT test will be executed during the study period: at baseline, week 12 and week 24 visits in order to assess progression free survival by CT.

The tests during the visits will be performed by a physician/nurse. Each subject will receive individual doses of AMOR-powder by escalating doses up to 1,800 mg of ACC powder per day (Amor powder administration will be continuous along the day - each eppendorf every two hours). Patients who will not be able to swallow the powder, will receive similar doses of ACC in tablets.

In addition, subject will inhale 1% ACC in 8 ml suspension, for inhalation three times a day.

Subject's functionality will be assessed by serially determining ECOG/Karnofsky performance status. Subject's progression free survival will be assessed by CT to evaluate tumor response to treatment.


Condition or disease Intervention/treatment Phase
Oncology Drug: Amorphous Calcium Carbonate (ACC) - Amor Phase 1

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Exploratory, Open Label Study to Improve the Function and Welfare of Late-stage Solid Cancer Subjects (With or Without Lung Involvement) by Amorphous Calcium Carbonate (ACC) Treatment, Administered Orally and Concomitantly With Inhalation
Actual Study Start Date : July 18, 2018
Estimated Primary Completion Date : June 2019
Estimated Study Completion Date : June 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Calcium

Arm Intervention/treatment
Experimental: Amorous Calcium Carbonate (ACC) - Amor

The investigational product will include:

  1. Amor powder, each eppendorf contains 200mg Calcium
  2. Amor Inhaled Double Pack - 1% ACC in 8 ml suspension
Drug: Amorphous Calcium Carbonate (ACC) - Amor
Amor Powder is composed of Amorphous Calcium Carbonate and is administered oral Amor Inhaled Double Pack is composed of 1% ACC in solution and is administered by inhalation




Primary Outcome Measures :
  1. Visual Analogue Scale (VAS) score for pain [ Time Frame: week 0, week 1, week 2, week 3, week 6, week 12, week 18, week 24 ]
    Assessing a change in Pain VAS score The scale is between 0-10. 0 is a score for no pain 5 is a score for moderate pain 10 is a score for unbearable pain

  2. ECOG Performance status (PS) [ Time Frame: week 0, week 1, week 2, week 3, week 6, week 12, week 18, week 24 ]
    Assessing a change in PS Grade 0 - Fully active, able to carry on all pre-disease performance without restriction Grade1 - Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work Grade 2 - Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours Grade 3 - Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours Grade 4 - Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair Grade 5 - Dead

  3. Oxygen saturation [ Time Frame: week 0, week 1, week 2, week 3, week 6, week 12, week 18, week 24 ]
    Assessing a change in oxygen saturation Normal pulse oximeter readings usually range from 95 to 100 percent. Values under 90 percent are considered low.

  4. Progression Free Survival [ Time Frame: week 0, week 12, week 24 ]
    Assessing a change from baseline in tumor's growth and size by using CT



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 119 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Males and females, age 18 years +
  2. Signed the informed consent
  3. Late Stage Histologically proven advanced solid tumours for which no standard of care therapy exist or failed or refused anti-cancer treatment
  4. Subject should not have any illness or condition deemed by the physician to contra-indicate treatment with ACC or may interfere with the assessment of the therapy
  5. Performance Status: ECOG 0-3/ Karnofsky performance status >50
  6. Life Expectancy : at least 2 months
  7. Hormonal therapy is allowed if needed
  8. Patient is on conservative treatment for relieving his symptoms
  9. Subjects within normal range of serum-corrected albumin calcium (between 7.0-10.5 mg/dl)
  10. Acceptable haematology and biochemistry variables:

    WBC ≥3000/mm3 Absolute Neutrophil count ≥ 1500 /mm3 Platelet Count ≥ 100,000/mm3 Hemoglobin ≥ 9 g/dL Bilirubin ≤ 1.5 x ULN ALT and AST ≤ 2.5 x ULN; for patients with hepatic metastases, ALT and AST ≤ 5 x ULN PT/PTT ≤ 1.5 ULN

  11. Subjects should have sufficient Vitamin D levels upon study entry, which is defined as 25(OH)D serum level >20 ng/mL (50 nmol/L) according to a document composed by the Food and Nutrition Board of the Institute of Medicine, USA. If the subject is Vitamin D insufficient or deficient, then a loading dose of Vitamin D3 will be administered during subject's enrollment or during the study as follows:

    1. If the serum 25(OH)D level is 12-20 ng/mL (30-50 nmol/L) then a loading oral dose of 50,000 IU of Vitamin D3 should be administered twice with 3-5 days in between the doses.
    2. If the serum 25(OH)D level is ≤ 12 ng/mL (30 nmol/L), then a loading oral dose of 50,000 IU of Vitamin D3 will be administered three times with 3-5 days in between the doses. Serum 25(OH)D levels will be checked 1-2 weeks following the last loading.
  12. Subjects receiving Denosumab or bisphosphonates are eligible. Denosumab or bisphosphonates can be administered during the study to alleviate bone metastasis pain.
  13. Negative Pregnancy Test.

Exclusion Criteria:

  1. Concurrent treatment with acute anti-cancer therapy
  2. Hypercalcemia or previous consistent reporting of hypercalcemia (serum calcium concentration > 12.0 mg/dL)
  3. Clinical Significant Cardiovascular Disease
  4. Known alcohol or drug abuse
  5. Any psychiatric condition that would prohibit understanding or rendering of Informed Consent
  6. Active Participation in Clinical Trial in the last 2 weeks prior to inclusion
  7. Brain metastases or spinal cord compression unless asymptomatic or treated and stable off steroids and anti-convulsants for at least 1 month prior to study treatment.
  8. Nephrolithiasis
  9. Pregnancy

    -


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03582280


Contacts
Layout table for location contacts
Contact: Julia Rothman, Dr. 0545250676 julia@amorphical.com

Locations
Layout table for location information
Israel
Hadassah Ein Carem Recruiting
Jerusalem, Israel
Contact: Hovav Nechustan, prof.    972-(0)2-6776911      
Principal Investigator: Hovav Nechustan, MD         
Sponsors and Collaborators
Amorphical Ltd.

Layout table for additonal information
Responsible Party: Amorphical Ltd.
ClinicalTrials.gov Identifier: NCT03582280     History of Changes
Other Study ID Numbers: AMCS-ONCO-004-1
First Posted: July 10, 2018    Key Record Dates
Last Update Posted: April 2, 2019
Last Verified: April 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Calcium, Dietary
Calcium Carbonate
Calcium
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Bone Density Conservation Agents
Antacids
Molecular Mechanisms of Pharmacological Action
Gastrointestinal Agents